Genovis evaluates new technology for early diagnosis of cardiovascular disease

Genovis signed an agreement with Repiratorius to test and evaluate RESP-3000 as a new biomarker for early diagnosis of cardiovascular disease using PET-Imaging. Genovis is coordinating the work, but GeccoDots AB, Genovis’ wholly owned subsidiary, will conduct the final evaluation. Work will begin immediately and the evaluation is expected to be completed in late 2013 or early 2014. 

The agreement includes the option for Genovis to acquire technology and patents relating to RESP-3000 in preclinical applications and Genovis intends to initiate negotiations for an acquisition if the tests show favorable results.

“The collaboration with Respiratorius provides us with a unique opportunity to develop innovative technology in medical imaging of patients with coronary artery disease, the most common type of heart disease which also includes myocardial infarction. The project is an excellent fit with the development projects and products now being commercialized at GeccoDots and has great commercial potential. We look forward to carrying out the evaluation study in cooperation with Respiratorius and researchers at Lund University,” says Sarah Fredriksson, CEO of Genovis.

About Respiratorius

Respiratorius AB (publ) develops drug candidates with the ambition to launch drugs for common diseases such as cancer, chronic obstructive pulmonary disease (COPD) and severe asthma. The project portfolio also includes a project for improving the diagnosis of cardiovascular disease (biomarker for PET-Imaging).

For more information, please contact: Sarah Fredriksson, CEO, Genovis AB Tel: 46 (0)46 -101235 sarah.fredriksson@genovis.com

ABOUT GENOVIS

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging.

Genovis shares are listed on NASDAQ OMX First North, and Thenberg Fondkommission is Certified Adviser for the Company, t: 46 (0)31-745 50 00

About Us

Genovis’ business concept is to develop, produce and market innovative technologies that facilitate and enable development of new treatment methods and diagnostics for customers in the medical device and pharmaceutical industries. The Group consists of Genovis AB and the subsidiary GeccoDots AB. Genovis develops and sells unique enzymes (protein engineering portfolio) in innovative product formats that facilitate development and quality control of and biological drugs. GeccoDots uses nanotechnology to produce a new type of contrast agent that is used in medical imaging. Genovis shares are listed on NASDAQ OMX First North

Subscribe

Documents & Links